ASAPF: AI 评分 48/100 — AI 分析 (4月 2026)

Aurora Spine Corporation develops and distributes minimally invasive interspinous fusion systems and devices. The company focuses on solutions for degenerative disc diseases and spinal stabilization, primarily in Canada.

Key Facts: AI Score: 48/100 Sector: Healthcare

公司概况

概要：

Aurora Spine Corporation, a Canadian medical device company, specializes in minimally invasive spinal fusion technologies, including interspinous fusion devices and interbody cages, targeting patients with degenerative disc diseases. With a focus on innovation and 3D-printed implants, Aurora Spine operates within the competitive medical device landscape.

ASAPF是做什么的？

Aurora Spine Corporation, established in 2013 and headquartered in Toronto, Canada, operates through its subsidiary, Aurora Spine, Inc., focusing on the design, development, and commercialization of minimally invasive spinal implant systems. The company's core business revolves around addressing spinal pathologies through innovative interspinous fusion and interbody technologies. Their product portfolio includes a range of interspinous process lumbar fusion devices like the ZIP family (ZIP, ZIP ULTRA, ZIP LP, and ZIP-51), designed to alleviate pain and stabilize the spine in patients with degenerative disc diseases. These devices offer a less invasive alternative to traditional spinal fusion surgeries. In addition to interspinous devices, Aurora Spine offers Ti-Coated polyether ether ketone (PEEK) interbody cages, which provide structural support and promote bone growth between vertebrae during fusion. The company also provides sterile-packed titanium plasma spray coated spinal infusion implants. Their interbody product line includes EOS, VOX, Echo, Echo SD, and EchoXL for lumbar applications, and Discovery for cervical procedures. Aurora Spine has also introduced SOLO, an anterior lumbar interbody fusion 3D printed stand-alone fusion device, and SiLo, a posterior fusion device for the sacroiliac joint. Further expanding their offerings, DEXA-C, a cervical interbody system, utilizes porous 3D-printed intervertebral body fusion devices with customizable lattice patterns to match individual patient bone quality. Aurora Spine primarily serves the Canadian market, focusing on providing advanced spinal solutions to improve patient outcomes and quality of life.

ASAPF的投资论点是什么？

Aurora Spine Corporation presents a focused investment opportunity within the medical device sector, specifically targeting the spinal fusion market. The company's emphasis on minimally invasive techniques and innovative products like the SOLO and DEXA-C devices could drive future growth. With a market capitalization of $0.02 billion, Aurora Spine operates with a negative P/E ratio of -11.66 and a negative profit margin of -7.4%, indicating potential for improved profitability. A gross margin of 59.7% suggests efficient production and pricing strategies. Key catalysts include expanding distribution networks and securing regulatory approvals for new products. However, investors should be aware of the risks associated with the OTC market and the company's current financial performance.

ASAPF在哪个行业运营？

Aurora Spine Corporation operates within the medical device industry, specifically focusing on spinal implants and fusion technologies. The global spinal implants and surgery devices market is projected to reach billions of dollars by 2026, driven by an aging population, increasing prevalence of spinal disorders, and advancements in minimally invasive surgical techniques. The competitive landscape includes established players like BTCY, CLCS, EMITF, GTHP, and IMMVF, as well as larger medical device companies. Aurora Spine differentiates itself through its focus on innovative designs, 3D-printed implants, and interspinous fusion devices.

Medical - Devices

Healthcare

ASAPF有哪些增长机遇？

Expansion into the US Market: Aurora Spine has the opportunity to expand its market reach into the United States, a significantly larger market for spinal implants. Securing FDA approval for its key products, such as the ZIP and SOLO systems, would be crucial for this expansion. The US spinal implant market is estimated to be worth billions of dollars annually, offering substantial revenue potential for Aurora Spine. Timeline: 2-3 years for regulatory approvals and market entry.
Increased Adoption of 3D-Printed Implants: Aurora Spine's DEXA-C cervical interbody system, which utilizes 3D-printed technology, presents a growth opportunity. As 3D printing becomes more prevalent in medical device manufacturing, Aurora Spine can capitalize on the demand for customized and porous implants that promote bone growth. The 3D-printed medical device market is experiencing rapid growth, driven by its ability to create patient-specific solutions. Timeline: Ongoing, with increasing adoption over the next 5 years.
Strategic Partnerships and Distribution Agreements: Forming strategic partnerships with hospitals, surgical centers, and distributors can accelerate Aurora Spine's market penetration. Collaborations with established players in the medical device industry can provide access to wider distribution networks and increased brand visibility. These partnerships can also facilitate the adoption of Aurora Spine's products by surgeons and healthcare providers. Timeline: 1-2 years to establish key partnerships.
Development of New Spinal Fusion Technologies: Investing in research and development to create new and innovative spinal fusion technologies can drive future growth. Focusing on areas such as motion preservation, regenerative medicine, and personalized implants can differentiate Aurora Spine from its competitors. Continuous innovation is essential for maintaining a competitive edge in the rapidly evolving medical device industry. Timeline: Ongoing, with new product launches every 2-3 years.
Focus on Minimally Invasive Surgical Techniques: The increasing demand for minimally invasive surgical procedures presents a growth opportunity for Aurora Spine. The company's ZIP system and other interspinous fusion devices align with this trend, offering patients less invasive alternatives to traditional spinal fusion. As more surgeons adopt minimally invasive techniques, the demand for Aurora Spine's products is expected to increase. Timeline: Ongoing, with increasing adoption over the next 5 years.

Market capitalization of $0.02 billion indicates a small-cap company with potential for growth.
Negative P/E ratio of -11.66 reflects current unprofitability, suggesting potential for future earnings improvement.
Gross margin of 59.7% demonstrates efficient cost management in product manufacturing and sales.
Beta of -0.54 suggests the stock is less volatile than the market, potentially offering stability during market downturns.
Focus on minimally invasive spinal fusion technologies positions the company in a growing segment of the medical device market.

ASAPF提供哪些产品和服务？

Develops minimally invasive interspinous fusion systems.
Distributes spinal implants and devices.
Offers interspinous process lumbar fusion devices (ZIP, ZIP ULTRA, ZIP LP, ZIP-51).
Provides Ti-Coated polyether ether ketone interbody cages.
Manufactures sterile-packed titanium plasma spray coated spinal infusion implants.
Offers interbody products (EOS, VOX, Echo, Echo SD, EchoXL, Discovery).
Provides SOLO, an anterior lumbar interbody fusion 3D printed stand-alone fusion device.
Offers SiLo, a posterior fusion device for the sacroiliac joint.

ASAPF如何赚钱？

Develops and manufactures spinal implants and devices.
Sells products directly to hospitals and surgical centers.
Utilizes distributors to reach a wider customer base.
Generates revenue through the sale of its spinal fusion products.

Hospitals
Surgical centers
Spinal surgeons
Patients suffering from degenerative disc diseases

Proprietary interspinous fusion technology (ZIP system).
Focus on minimally invasive surgical techniques.
3D-printed implant capabilities (DEXA-C).
Established presence in the Canadian market.

什么因素可能推动ASAPF股价上涨？

Upcoming: FDA approval for key products (ZIP, SOLO) for US market entry.
Upcoming: Strategic partnerships with hospitals and surgical centers to expand distribution.
Ongoing: Increasing adoption of 3D-printed implants in spinal fusion procedures.
Ongoing: Development and launch of new spinal fusion technologies.
Ongoing: Expansion of sales and marketing efforts in the Canadian market.

ASAPF的主要风险是什么？

Potential: Competition from larger medical device companies with greater resources.
Potential: Regulatory hurdles and delays in obtaining FDA approvals.
Potential: Product liability and litigation risks associated with spinal implants.
Ongoing: Negative profitability and reliance on external funding.
Ongoing: Limited market presence outside of Canada.

ASAPF的核心优势是什么？

Innovative interspinous fusion technology.
Focus on minimally invasive solutions.
3D-printing capabilities for customized implants.
Established distribution network in Canada.

ASAPF的劣势是什么？

Limited market presence outside of Canada.
Negative profitability and reliance on external funding.
Small market capitalization and limited resources.
Dependence on key product lines.

ASAPF有哪些机遇？

Expansion into the US market.
Increased adoption of 3D-printed implants.
Strategic partnerships and distribution agreements.
Development of new spinal fusion technologies.

ASAPF面临哪些威胁？

Competition from larger medical device companies.
Regulatory hurdles and approval processes.
Product liability and litigation risks.
Economic downturns and healthcare spending cuts.

ASAPF的竞争对手是谁？

Biotech Company — Focuses on regenerative medicine for spinal disorders. — (BTCY)
Calcivis — Develops dental imaging devices. — (CLCS)
Emmis Communications Corporation — Operates in the media and broadcasting industry. — (EMITF)
G Medical Innovations Holdings Ltd — Develops mobile health and e-health solutions. — (GTHP)
Immuron Limited — Develops and commercializes microbiome-based therapies. — (IMMVF)

Key Metrics

MoonshotScore: 48/100

Company Profile

CEO: Trent J. Northcutt
Headquarters: Toronto, CA
Founded: 2013

AI Insight

AI analysis pending for ASAPF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Aurora Spine Corporation do?

Aurora Spine Corporation is a medical device company specializing in the design, development, and commercialization of minimally invasive spinal implant systems. The company's primary focus is on providing solutions for patients suffering from degenerative disc diseases and other spinal conditions. Their product portfolio includes interspinous fusion devices, interbody cages, and 3D-printed implants, all designed to improve patient outcomes and quality of life. Aurora Spine primarily serves the Canadian market, offering advanced spinal solutions to hospitals, surgical centers, and spinal surgeons.

What do analysts say about ASAPF stock?

As of 2026-03-16, formal analyst ratings for Aurora Spine Corporation (ASAPF) are limited due to its OTC listing and small market capitalization. Key valuation metrics include a negative P/E ratio, reflecting current unprofitability, and a gross margin of 59.7%, indicating efficient cost management. Growth considerations center on the company's ability to expand into the US market, secure regulatory approvals, and increase adoption of its innovative spinal fusion technologies. Investors should conduct their own due diligence and consider the risks associated with OTC-listed stocks.

What are the main risks for ASAPF?

Aurora Spine Corporation faces several risks, including competition from larger medical device companies, regulatory hurdles in obtaining FDA approvals for US market expansion, and potential product liability claims associated with spinal implants. The company's negative profitability and reliance on external funding also pose financial risks. Additionally, its limited market presence outside of Canada and dependence on key product lines could impact future growth. Investors should carefully consider these risks before investing in ASAPF.